OSAKA, Japan & CAMBRIDGE, Mass., January 20, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it was one of only 11 companies to achieve global Top Employer® certification for 2022, marking the fifth consecutive year that it has been recognized for outstanding people policies and practices worldwide. In addition to the global certification, Takeda is also recognized as a Top Employer across four regions and 39 countries, reinforcing its steadfast co
OSAKA, Japan & CAMBRIDGE, Mass., January 10, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth and additional upside potential through FY2030. Presenting at the 40th Annual J.P. Morgan Healthcare Conference, Christophe Weber, Takeda’s President and Chief Executive Officer, reinforced the mid-term revenue growth potential of its 14 global
OSAKA, Japan & LONDON, January 10, 2022--Takeda exercised its option to acquire Adaptate Biotherapeutics, adding a gamma delta T-cell engager platform to Takeda's immuno-oncology portfolio.